BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Eli Lilly Netherlands B.V.  submitted on 10 October 2003 an application for Marketing 
Authorisation to the European Medicines Agency (EMEA) for CYMBALTA, through the centralised 
procedure.  After  agreement  by  the  CHMP  on  25  September  2003,  this  medicinal  product  has  been 
referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  Dr. Gonzalo Calvo-Rojas 
Co-Rapporteur:  Dr. Tomas Salmonson 
Scientific Advice: 
The applicant received Scientific Advice from the CHMP on 19 November 1998. The Scientific 
Advice pertained to the clinical part of the dossier.  
Licensing status: 
The product was not authorised in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The application was received by the EMEA on 10 October 2003.  
The procedure started on 27 October 2003. 
The  Rapporteur's  first  Assessment Report was circulated to  all  CHMP  members on  9 January 
2004 . The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 
12 January 2004  
During  the  meeting  on  24–26  February  2004,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on  26 February 2004. 
The applicant submitted the responses to the CHMP consolidated List of Questions on 16 April 
2004. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on  1 June 2004. 
During  the  CHMP  meeting  on  22–23  June  2004,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing by the applicant. 
The applicant submitted the responses in writing to the CHMP list of outstanding issues on 10 
August 2004.  
During  the  meeting  on    14-16  September  2004,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Cymbalta on 16 September 2004. The applicant provided 
the  letter  of  undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  on  15 
September 2004. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
